The past decade witnessed an increasing role for GLP-1 agonists in the management of metabolic disorders, including DM, obesity, and metabolic-dysfunction-associated steatohepatitis (MASH), as well as cardio-renal protective effects. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.